VIAF

Virtual International Authority File

Search

Leader 00000nz a2200037n 45 0
001 WKP|Q59123234 (VIAF cluster) (Authority/Source Record)
003 WKP
005 20241121000211.0
008 241121nneanz||abbn n and d
035 ‎‡a (WKP)Q59123234‏
024 ‎‡a 0000-0003-4649-0095‏ ‎‡2 orcid‏
024 ‎‡a 55876579100‏ ‎‡2 scopus‏
035 ‎‡a (OCoLC)Q59123234‏
100 0 ‎‡a Alejandro Ibáñez-Costa‏ ‎‡c researcher ORCID ID = 0000-0003-4649-0095‏ ‎‡9 en‏
375 ‎‡a 1‏ ‎‡2 iso5218‏
400 0 ‎‡a Alejandro Ibáñez-Costa‏ ‎‡c wetenschapper‏ ‎‡9 nl‏
670 ‎‡a Author's A Somatostatin Receptor Subtype-3 (SST3) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary Tumors‏
670 ‎‡a Author's Association between radiological parameters and clinical and molecular characteristics in human somatotropinomas.‏
670 ‎‡a Author's Biguanides exert antitumoral actions in pituitary tumor cells through AMPK-dependent and -independent mechanisms‏
670 ‎‡a Author's BIM-23A760 influences key functional endpoints in pituitary adenomas and normal pituitaries: molecular mechanisms underlying the differential response in adenomas‏
670 ‎‡a Author's Cortistatin: A new link between the growth hormone/prolactin axis, stress, and metabolism.‏
670 ‎‡a Author's Desmopressin test in the diagnosis and follow-up of cyclical Cushing's disease.‏
670 ‎‡a Author's Dietary fat alters the expression of cortistatin and ghrelin systems in the PBMCs of elderly subjects: putative implications in the postprandial inflammatory response‏
670 ‎‡a Author's Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cancer stem cells with an anti-splicing drug‏
670 ‎‡a Author's E-cadherin expression is associated with somatostatin analogue response in acr Omega ly‏
670 ‎‡a Author's Early restoration of immune and vascular phenotypes in systemic lupus erythematosus and rheumatoid arthritis patients after B cell depletion‏
670 ‎‡a Author's Ghrelin gene products, receptors, and GOAT enzyme: biological and pathophysiological insight.‏
670 ‎‡a Author's Ghrelin O-acyltransferase (GOAT) enzyme is overexpressed in prostate cancer, and its levels are associated with patient's metabolic status: Potential value as a non-invasive biomarker.‏
670 ‎‡a Author's In1-ghrelin, a splice variant of ghrelin gene, is associated with the evolution and aggressiveness of human neuroendocrine tumors: Evidence from clinical, cellular and molecular parameters‏
670 ‎‡a Author's In1-ghrelin splicing variant is overexpressed in pituitary adenomas and increases their aggressive features.‏
670 ‎‡a Author's Melatonin regulates somatotrope and lactotrope function through common and distinct signaling pathways in cultured primary pituitary cells from female primates‏
670 ‎‡a Author's Molecular Characterization of Growth Hormone-producing Tumors in the GC Rat Model of Acr Omega ly‏
670 ‎‡a Author's Obestatin plays an opposite role in the regulation of pituitary somatotrope and corticotrope function in female primates and male/female mice.‏
670 ‎‡a Author's Octreotide and pasireotide‏
670 ‎‡a Author's Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitro.‏
670 ‎‡a Author's Oncogenic Role of Secreted Engrailed Homeobox 2 (EN2) in Prostate Cancer‏
670 ‎‡a Author's Presence of sst5TMD4, a truncated splice variant of the somatostatin receptor subtype 5, is associated to features of increased aggressiveness in pancreatic neuroendocrine tumors.‏
670 ‎‡a Author's Somatotropinomas, but not nonfunctioning pituitary adenomas, maintain a functional apoptotic RET/Pit1/ARF/p53 pathway that is blocked by excess GDNF.‏
670 ‎‡a Author's Splicing machinery is impaired in rheumatoid arthritis, associated with disease activity and modulated by anti-TNF therapy‏
670 ‎‡a Author's The expression of the truncated isoform of somatostatin receptor subtype 5 associates with aggressiveness in medullary thyroid carcinoma cells‏
670 ‎‡a Author's The Molecular Registry of Pituitary Adenomas (REMAH): A bet of Spanish Endocrinology for the future of individualized medicine and translational research.‏
670 ‎‡a Author's The oncogenic role of the In1-ghrelin splicing variant in prostate cancer aggressiveness‏
670 ‎‡a Author's The oncogenic role of the spliced somatostatin receptor sst5TMD4 variant in prostate cancer.‏
670 ‎‡a Author's The truncated somatostatin receptor sst5TMD4 stimulates the angiogenic process and is associated to lymphatic metastasis and disease-free survival in breast cancer patients‏
670 ‎‡a Author's Truncated somatostatin receptor variant sst5TMD4 confers aggressive features (proliferation, invasion and reduced octreotide response) to somatotropinomas‏
909 ‎‡a (orcid) 0000000346490095‏ ‎‡9 1‏
909 ‎‡a (scopus) 55876579100‏ ‎‡9 1‏
919 ‎‡a truncatedsomatostatinreceptorvariantsst5tmd4confersaggressivefeaturesproliferationinvasionandreducedoctreotideresponsetosomatotropinomas‏ ‎‡A Truncated somatostatin receptor variant sst5TMD4 confers aggressive features (proliferation, invasion and reduced octreotide response) to somatotropinomas‏ ‎‡9 1‏
919 ‎‡a truncatedsomatostatinreceptorsst5tmd4stimulatestheangiogenicprocessandisassociatedtolymphaticmetastasisanddiseasefreesurvivalinbreastcancerpatients‏ ‎‡A The truncated somatostatin receptor sst5TMD4 stimulates the angiogenic process and is associated to lymphatic metastasis and disease-free survival in breast cancer patients‏ ‎‡9 1‏
919 ‎‡a oncogenicroleofthesplicedsomatostatinreceptorsst5tmd4variantinprostatecancer‏ ‎‡A The oncogenic role of the spliced somatostatin receptor sst5TMD4 variant in prostate cancer.‏ ‎‡9 1‏
919 ‎‡a oncogenicroleofthein1ghrelinsplicingvariantinprostatecanceraggressiveness‏ ‎‡A The oncogenic role of the In1-ghrelin splicing variant in prostate cancer aggressiveness‏ ‎‡9 1‏
919 ‎‡a molecularregistryofpituitaryadenomasremahabetofspanishendocrinologyforthefutureofindividualizedmedicineandtranslationalresearch‏ ‎‡A The Molecular Registry of Pituitary Adenomas (REMAH): A bet of Spanish Endocrinology for the future of individualized medicine and translational research.‏ ‎‡9 1‏
919 ‎‡a earlyrestorationofimmuneandvascularphenotypesinsystemiclupuserythematosusandrheumatoidarthritispatientsafterbcelldepletion‏ ‎‡A Early restoration of immune and vascular phenotypes in systemic lupus erythematosus and rheumatoid arthritis patients after B cell depletion‏ ‎‡9 1‏
919 ‎‡a expressionofthetruncatedisoformofsomatostatinreceptorsubtype5associateswithaggressivenessinmedullarythyroidcarcinomacells‏ ‎‡A The expression of the truncated isoform of somatostatin receptor subtype 5 associates with aggressiveness in medullary thyroid carcinoma cells‏ ‎‡9 1‏
919 ‎‡a splicingmachineryisimpairedinrheumatoidarthritisassociatedwithdiseaseactivityandmodulatedbyantitnftherapy‏ ‎‡A Splicing machinery is impaired in rheumatoid arthritis, associated with disease activity and modulated by anti-TNF therapy‏ ‎‡9 1‏
919 ‎‡a somatotropinomasbutnotnonfunctioningpituitaryadenomasmaintainafunctionalapoptoticretpit1arfp53pathwaythatisblockedbyexcessgdnf‏ ‎‡A Somatotropinomas, but not nonfunctioning pituitary adenomas, maintain a functional apoptotic RET/Pit1/ARF/p53 pathway that is blocked by excess GDNF.‏ ‎‡9 1‏
919 ‎‡a presenceofsst5tmd4atruncatedsplicevariantofthesomatostatinreceptorsubtype5isassociatedtofeaturesofincreasedaggressivenessinpancreaticneuroendocrinetumors‏ ‎‡A Presence of sst5TMD4, a truncated splice variant of the somatostatin receptor subtype 5, is associated to features of increased aggressiveness in pancreatic neuroendocrine tumors.‏ ‎‡9 1‏
919 ‎‡a oncogenicroleofsecretedengrailedhomeobox2en2inprostatecancer‏ ‎‡A Oncogenic Role of Secreted Engrailed Homeobox 2 (EN2) in Prostate Cancer‏ ‎‡9 1‏
919 ‎‡a octreotideandpasireotidedissimilarlyinhibitpituitarytumorcellsinvitro‏ ‎‡A Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitro.‏ ‎‡9 1‏
919 ‎‡a ghrelingeneproductsreceptorsandgoatenzymebiologicalandpathophysiologicalinsight‏ ‎‡A Ghrelin gene products, receptors, and GOAT enzyme: biological and pathophysiological insight.‏ ‎‡9 1‏
919 ‎‡a octreotideandpasireotide‏ ‎‡A Octreotide and pasireotide‏ ‎‡9 1‏
919 ‎‡a obestatinplaysanoppositeroleintheregulationofpituitarysomatotropeandcorticotropefunctioninfemaleprimatesandmalefemalemice‏ ‎‡A Obestatin plays an opposite role in the regulation of pituitary somatotrope and corticotrope function in female primates and male/female mice.‏ ‎‡9 1‏
919 ‎‡a molecularcharacterizationofgrowthhormoneproducingtumorsinthegcratmodelofacr Omega ly‏ ‎‡A Molecular Characterization of Growth Hormone-producing Tumors in the GC Rat Model of Acr Omega ly‏ ‎‡9 1‏
919 ‎‡a melatoninregulatessomatotropeandlactotropefunctionthroughcommonanddistinctsignalingpathwaysinculturedprimarypituitarycellsfromfemaleprimates‏ ‎‡A Melatonin regulates somatotrope and lactotrope function through common and distinct signaling pathways in cultured primary pituitary cells from female primates‏ ‎‡9 1‏
919 ‎‡a ghrelinoacyltransferasegoatenzymeisoverexpressedinprostatecanceranditslevelsareassociatedwithpatientsmetabolicstatuspotentialvalueasanoninvasivebiomarker‏ ‎‡A Ghrelin O-acyltransferase (GOAT) enzyme is overexpressed in prostate cancer, and its levels are associated with patient's metabolic status: Potential value as a non-invasive biomarker.‏ ‎‡9 1‏
919 ‎‡a in1ghrelinasplicevariantofghrelingeneisassociatedwiththeevolutionandaggressivenessofhumanneuroendocrinetumorsevidencefromclinicalcellularandmolecularparameters‏ ‎‡A In1-ghrelin, a splice variant of ghrelin gene, is associated with the evolution and aggressiveness of human neuroendocrine tumors: Evidence from clinical, cellular and molecular parameters‏ ‎‡9 1‏
919 ‎‡a in1ghrelinsplicingvariantisoverexpressedinpituitaryadenomasandincreasestheiraggressivefeatures‏ ‎‡A In1-ghrelin splicing variant is overexpressed in pituitary adenomas and increases their aggressive features.‏ ‎‡9 1‏
919 ‎‡a somatostatinreceptorsubtype3sst3peptideagonistshowsantitumoreffectsinexperimentalmodelsofnonfunctioningpituitarytumors‏ ‎‡A A Somatostatin Receptor Subtype-3 (SST3) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary Tumors‏ ‎‡9 1‏
919 ‎‡a associationbetweenradiologicalparametersandclinicalandmolecularcharacteristicsinhumansomatotropinomas‏ ‎‡A Association between radiological parameters and clinical and molecular characteristics in human somatotropinomas.‏ ‎‡9 1‏
919 ‎‡a biguanidesexertantitumoralactionsinpituitarytumorcellsthroughampkdependentandindependentmechanisms‏ ‎‡A Biguanides exert antitumoral actions in pituitary tumor cells through AMPK-dependent and -independent mechanisms‏ ‎‡9 1‏
919 ‎‡a bim23a760influenceskeyfunctionalendpointsinpituitaryadenomasandnormalpituitariesmolecularmechanismsunderlyingthedifferentialresponseinadenomas‏ ‎‡A BIM-23A760 influences key functional endpoints in pituitary adenomas and normal pituitaries: molecular mechanisms underlying the differential response in adenomas‏ ‎‡9 1‏
919 ‎‡a cortistatinanewlinkbetweenthegrowthhormoneprolactinaxisstressandmetabolism‏ ‎‡A Cortistatin: A new link between the growth hormone/prolactin axis, stress, and metabolism.‏ ‎‡9 1‏
919 ‎‡a desmopressintestinthediagnosisandfollowupofcyclicalcushingsdisease‏ ‎‡A Desmopressin test in the diagnosis and follow-up of cyclical Cushing's disease.‏ ‎‡9 1‏
919 ‎‡a dietaryfatalterstheexpressionofcortistatinandghrelinsystemsinthepbmcsofelderlysubjectsputativeimplicationsinthepostprandialinflammatoryresponse‏ ‎‡A Dietary fat alters the expression of cortistatin and ghrelin systems in the PBMCs of elderly subjects: putative implications in the postprandial inflammatory response‏ ‎‡9 1‏
919 ‎‡a dysregulatedsplicingfactorsf3b1unveilsadualtherapeuticvulnerabilitytotargetpancreaticcancercellsandcancerstemcellswithanantisplicingdrug‏ ‎‡A Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cancer stem cells with an anti-splicing drug‏ ‎‡9 1‏
919 ‎‡a ecadherinexpressionisassociatedwithsomatostatinanalogueresponseinacr Omega ly‏ ‎‡A E-cadherin expression is associated with somatostatin analogue response in acr Omega ly‏ ‎‡9 1‏
946 ‎‡a b‏ ‎‡9 1‏
996 ‎‡2 LC|n 2009053224‏
996 ‎‡2 ISNI|0000000068813252‏
996 ‎‡2 PTBNP|771052‏
996 ‎‡2 LC|n 98111481‏
996 ‎‡2 BLBNB|000466995‏
996 ‎‡2 PTBNP|1455786‏
996 ‎‡2 DNB|1207570974‏
996 ‎‡2 BNC|981058599267606706‏
996 ‎‡2 PTBNP|1890455‏
996 ‎‡2 ISNI|0000000069615098‏
996 ‎‡2 BLBNB|001029384‏
996 ‎‡2 LC|no2001064089‏
996 ‎‡2 NSK|000164874‏
996 ‎‡2 DNB|1064960960‏
996 ‎‡2 DNB|1060818132‏
996 ‎‡2 JPG|500230467‏
996 ‎‡2 ISNI|0000000035252081‏
996 ‎‡2 BLBNB|000166983‏
996 ‎‡2 ISNI|0000000067656427‏
996 ‎‡2 DNB|122879066‏
996 ‎‡2 PTBNP|1382900‏
996 ‎‡2 PTBNP|51957‏
996 ‎‡2 PTBNP|284429‏
996 ‎‡2 ISNI|0000000036018991‏
996 ‎‡2 RERO|A011866798‏
996 ‎‡2 BIBSYS|90858882‏
996 ‎‡2 ISNI|000000006849620X‏
996 ‎‡2 LC|no2005016149‏
996 ‎‡2 SUDOC|189318139‏
996 ‎‡2 ICCU|CUBV048705‏
996 ‎‡2 ISNI|0000000452560464‏
996 ‎‡2 ISNI|0000000066641581‏
996 ‎‡2 PTBNP|1878577‏
996 ‎‡2 ISNI|0000000070312940‏
996 ‎‡2 ISNI|0000000046049900‏
996 ‎‡2 PTBNP|1332823‏
996 ‎‡2 DNB|1137077557‏
996 ‎‡2 BNE|XX830127‏
996 ‎‡2 ISNI|0000000069084696‏
996 ‎‡2 ISNI|0000000048661220‏
996 ‎‡2 NUKAT|n 2005083414‏
996 ‎‡2 SUDOC|075412993‏
996 ‎‡2 PTBNP|238113‏
996 ‎‡2 PTBNP|1338252‏
996 ‎‡2 PTBNP|169354‏
996 ‎‡2 BNF|15020251‏
996 ‎‡2 BLBNB|000508448‏
996 ‎‡2 BLBNB|000177430‏
996 ‎‡2 LC|n 2018251655‏
996 ‎‡2 BAV|495_381103‏
996 ‎‡2 DNB|1219682330‏
996 ‎‡2 PTBNP|1660420‏
996 ‎‡2 PTBNP|165825‏
996 ‎‡2 BLBNB|000469923‏
996 ‎‡2 LC|no2016037249‏
996 ‎‡2 ISNI|0000000068901324‏
996 ‎‡2 ISNI|0000000070006847‏
996 ‎‡2 J9U|987007329430605171‏
996 ‎‡2 DNB|1020441437‏
996 ‎‡2 ISNI|000000006992750X‏
996 ‎‡2 LC|n 96088177‏
996 ‎‡2 SUDOC|154220590‏
996 ‎‡2 BLBNB|000328227‏
996 ‎‡2 BLBNB|000557235‏
996 ‎‡2 ISNI|0000000025265786‏
996 ‎‡2 SUDOC|270849521‏
996 ‎‡2 SUDOC|130531456‏
996 ‎‡2 PTBNP|1389585‏
996 ‎‡2 SUDOC|02665279X‏
996 ‎‡2 BNF|13776280‏
996 ‎‡2 NTA|087743388‏
996 ‎‡2 SUDOC|199671184‏
996 ‎‡2 J9U|987007344280905171‏
996 ‎‡2 NTA|072570512‏
996 ‎‡2 BLBNB|000464181‏
996 ‎‡2 PTBNP|90207‏
996 ‎‡2 PTBNP|1888064‏
996 ‎‡2 PTBNP|152644‏
996 ‎‡2 SUDOC|250665573‏
996 ‎‡2 BNF|17059426‏
996 ‎‡2 BLBNB|001574599‏
996 ‎‡2 SUDOC|190234423‏
996 ‎‡2 LC|n 85816449‏
996 ‎‡2 SUDOC|194974537‏
996 ‎‡2 LC|n 2024252011‏
996 ‎‡2 ISNI|0000000068088783‏
996 ‎‡2 NTA|388115270‏
996 ‎‡2 PTBNP|1930703‏
996 ‎‡2 ISNI|0000000068497587‏
996 ‎‡2 LC|nr2004027852‏
996 ‎‡2 ISNI|0000000068797483‏
996 ‎‡2 BIBSYS|12040249‏
996 ‎‡2 PTBNP|227774‏
996 ‎‡2 PTBNP|146149‏
996 ‎‡2 ISNI|0000000070331498‏
996 ‎‡2 ISNI|000000004820429X‏
996 ‎‡2 BLBNB|000353133‏
996 ‎‡2 PTBNP|116796‏
996 ‎‡2 BLBNB|000166981‏
996 ‎‡2 PTBNP|234523‏
996 ‎‡2 PTBNP|258316‏
996 ‎‡2 LC|no2013114101‏
996 ‎‡2 BLBNB|001502982‏
996 ‎‡2 BNC|981058511825306706‏
996 ‎‡2 BLBNB|000524339‏
996 ‎‡2 PTBNP|158242‏
996 ‎‡2 SUDOC|19558385X‏
996 ‎‡2 PTBNP|1788274‏
996 ‎‡2 ISNI|0000000040215218‏
996 ‎‡2 PTBNP|66731‏
996 ‎‡2 NTA|108097137‏
996 ‎‡2 CAOONL|ncf10582745‏
996 ‎‡2 ISNI|0000000069403378‏
996 ‎‡2 ICCU|CFIV248156‏
996 ‎‡2 ISNI|0000000068614026‏
996 ‎‡2 ISNI|0000000121291183‏
996 ‎‡2 BLBNB|000567813‏
996 ‎‡2 BNE|XX5494611‏
996 ‎‡2 LC|no2018071107‏
996 ‎‡2 BNF|18103230‏
996 ‎‡2 ISNI|0000000072934225‏
996 ‎‡2 BNF|17708750‏
996 ‎‡2 DNB|1057203920‏
996 ‎‡2 ISNI|0000000512765446‏
996 ‎‡2 SUDOC|194986268‏
996 ‎‡2 PTBNP|230851‏
996 ‎‡2 N6I|vtls000080713‏
996 ‎‡2 ISNI|0000000390022555‏
996 ‎‡2 SUDOC|26158829X‏
996 ‎‡2 BLBNB|001433496‏
996 ‎‡2 PTBNP|142211‏
996 ‎‡2 NTA|108242765‏
996 ‎‡2 PTBNP|183150‏
996 ‎‡2 PTBNP|210139‏
996 ‎‡2 PTBNP|51752‏
996 ‎‡2 PTBNP|1393289‏
996 ‎‡2 PTBNP|257500‏
996 ‎‡2 BNC|981058516206306706‏
996 ‎‡2 ISNI|0000000419579200‏
996 ‎‡2 LC|no2001091693‏
996 ‎‡2 ISNI|0000000418120828‏
996 ‎‡2 DNB|1260522970‏
996 ‎‡2 LC|n 85190983‏
996 ‎‡2 ISNI|0000000121323587‏
996 ‎‡2 SUDOC|103575456‏
996 ‎‡2 BNE|XX1034526‏
996 ‎‡2 BIBSYS|12040290‏
996 ‎‡2 DNB|109065748X‏
996 ‎‡2 ISNI|0000000051305315‏
996 ‎‡2 SUDOC|273934430‏
996 ‎‡2 NTA|364161027‏
996 ‎‡2 BNC|981058527057406706‏
996 ‎‡2 DNB|1281802131‏
996 ‎‡2 ISNI|0000000389014531‏
996 ‎‡2 PTBNP|175886‏
996 ‎‡2 ISNI|0000000069398062‏
996 ‎‡2 BNE|XX1600422‏
996 ‎‡2 LC|n 2020250459‏
996 ‎‡2 PTBNP|285765‏
996 ‎‡2 DE633|pe40209624‏
996 ‎‡2 NSK|000528571‏
996 ‎‡2 PTBNP|46320‏
996 ‎‡2 LC|n 2024255882‏
996 ‎‡2 PTBNP|242785‏
996 ‎‡2 RERO|A006012250‏
996 ‎‡2 NUKAT|n 2016005734‏
996 ‎‡2 SUDOC|031657885‏
996 ‎‡2 PTBNP|148787‏
996 ‎‡2 BNF|12283147‏
996 ‎‡2 DNB|116689013‏
996 ‎‡2 BLBNB|000453888‏
996 ‎‡2 CAOONL|ncf10733467‏
996 ‎‡2 LC|no2017056469‏
996 ‎‡2 DNB|1057430013‏
996 ‎‡2 LC|n 2023252676‏
996 ‎‡2 PTBNP|1756641‏
996 ‎‡2 BLBNB|000457310‏
996 ‎‡2 PTBNP|157380‏
996 ‎‡2 ISNI|0000000069926259‏
996 ‎‡2 NUKAT|n 2020004784‏
996 ‎‡2 PTBNP|1380814‏
996 ‎‡2 PTBNP|284517‏
996 ‎‡2 LC|no2012142024‏
996 ‎‡2 LC|no2008175575‏
996 ‎‡2 LC|no2022078503‏
996 ‎‡2 NKC|jo20181009833‏
996 ‎‡2 DNB|1056180706‏
996 ‎‡2 ISNI|0000000067651634‏
996 ‎‡2 ICCU|CFIV041230‏
996 ‎‡2 PTBNP|87169‏
996 ‎‡2 BNE|XX1725895‏
996 ‎‡2 SUDOC|192192795‏
996 ‎‡2 BLBNB|001648372‏
996 ‎‡2 ISNI|0000000080960183‏
996 ‎‡2 BNF|17159883‏
996 ‎‡2 ISNI|0000000385409608‏
996 ‎‡2 BLBNB|000272540‏
996 ‎‡2 PTBNP|1454935‏
996 ‎‡2 ISNI|0000000068396460‏
996 ‎‡2 BNE|XX5781026‏
996 ‎‡2 LC|no2004072630‏
996 ‎‡2 ISNI|0000000110457950‏
996 ‎‡2 NUKAT|n 2020013794‏
996 ‎‡2 DNB|1057642568‏
996 ‎‡2 ISNI|000000008333353X‏
996 ‎‡2 PTBNP|70994‏
996 ‎‡2 PTBNP|325643‏
996 ‎‡2 J9U|987007451475005171‏
996 ‎‡2 PTBNP|1627012‏
996 ‎‡2 PTBNP|51658‏
996 ‎‡2 ICCU|UFIV151003‏
996 ‎‡2 SUDOC|230646573‏
996 ‎‡2 LC|n 2013075823‏
996 ‎‡2 BNE|XX5471715‏
996 ‎‡2 ISNI|0000000069315079‏
996 ‎‡2 PTBNP|1520752‏
996 ‎‡2 ISNI|0000000444135337‏
996 ‎‡2 LC|n 2024253681‏
996 ‎‡2 ISNI|0000000078470150‏
996 ‎‡2 PLWABN|9810633206205606‏
996 ‎‡2 DNB|1047963124‏
996 ‎‡2 BLBNB|000585548‏
996 ‎‡2 NKC|hka20181007305‏
996 ‎‡2 LC|n 80146163‏
996 ‎‡2 LC|no2023107170‏
996 ‎‡2 PTBNP|234415‏
996 ‎‡2 RERO|A011425966‏
996 ‎‡2 ISNI|0000000053106459‏
996 ‎‡2 BIBSYS|90823010‏
996 ‎‡2 SUDOC|144601826‏
996 ‎‡2 ICCU|MUSV018516‏
996 ‎‡2 ISNI|0000000045057589‏
996 ‎‡2 BLBNB|001564973‏
996 ‎‡2 ISNI|0000000079816336‏
996 ‎‡2 ISNI|0000000070416758‏
996 ‎‡2 RERO|A013548148‏
996 ‎‡2 BLBNB|001506130‏
996 ‎‡2 ISNI|0000000068497755‏
996 ‎‡2 LC|n 97048024‏
996 ‎‡2 DNB|188356568‏
996 ‎‡2 BIBSYS|90937239‏
996 ‎‡2 PTBNP|218182‏
996 ‎‡2 BNF|11886807‏
996 ‎‡2 NUKAT|n 2008123925‏
996 ‎‡2 LIH|LNB:C_y__v_U;=CX‏
996 ‎‡2 BLBNB|001505109‏
996 ‎‡2 DNB|1057750476‏
996 ‎‡2 DNB|138986002‏
996 ‎‡2 PTBNP|51662‏
996 ‎‡2 ISNI|0000000122092071‏
997 ‎‡a 0 0 lived 0 0‏ ‎‡9 1‏